These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 33722538)

  • 1. Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation Therapies.
    Lim C; Sinha P; Harrison SJ; Quach H; Slavin MA; Teh BW
    Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):444-450.e3. PubMed ID: 33722538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy.
    Teh BW; Harrison SJ; Worth LJ; Spelman T; Thursky KA; Slavin MA
    Br J Haematol; 2015 Oct; 171(1):100-8. PubMed ID: 26105211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world renal function among patients with multiple myeloma in the United States.
    Mikhael J; Singh E; Rice MS
    Blood Cancer J; 2021 May; 11(5):99. PubMed ID: 34021119
    [No Abstract]   [Full Text] [Related]  

  • 4. Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital.
    Teh BW; Worth LJ; Harrison SJ; Thursky KA; Slavin MA
    Support Care Cancer; 2015 Jul; 23(7):1901-6. PubMed ID: 25487843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.
    Fradley MG; Groarke JD; Laubach J; Alsina M; Lenihan DJ; Cornell RF; Maglio M; Shain KH; Richardson PG; Moslehi J
    Br J Haematol; 2018 Jan; 180(2):271-275. PubMed ID: 29048105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta-analysis of randomized clinical trials.
    Das A; Dasgupta S; Gong Y; Shah UA; Fradley MG; Cheng RK; Roy B; Guha A
    Hematol Oncol; 2022 Apr; 40(2):233-242. PubMed ID: 34940983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low rates of invasive fungal disease in patients with multiple myeloma managed with new generation therapies: Results from a multi-centre cohort study.
    Lim C; Sinha P; Harrison SJ; Quach H; Slavin MA; Teh BW
    Mycoses; 2021 Jan; 64(1):30-34. PubMed ID: 32885525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of adverse events associated with front-line anti-myeloma treatment in Medicare patients with multiple myeloma.
    Chen Y; Lairson DR; Chan W; Du XL
    Ann Hematol; 2018 May; 97(5):851-863. PubMed ID: 29333596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infectious Complications in Patients With Multiple Myeloma After High-Dose Chemotherapy Followed by Autologous Stem Cell Transplant: Nationwide Study of the Infectious Complications Study Group of the Polish Adult Leukemia Group.
    Waszczuk-Gajda A; Drozd-Sokołowska J; Basak GW; Piekarska A; Mensah-Glanowska P; Sadowska-Klasa A; Wierzbowska A; Rzepecki P; Tomaszewska A; Mańko J; Hus M; Adamska M; Romejko-Jarosińska J; Dybko J; Biernat M; Kyrcz-Krzemień S; Sędzimirska M; Winciorek N; Jędrzejczak WW; Styczyński J; Giebel S; Gil L
    Transplant Proc; 2020 Sep; 52(7):2178-2185. PubMed ID: 32217016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Anti-CD38 Antibody Therapy in Multiple Myeloma.
    Petrucci MT; Vozella F
    Cells; 2019 Dec; 8(12):. PubMed ID: 31842517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma.
    Zanwar S; Ho M; Kapoor P; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Hayman SR; Dingli D; Kourelis T; Fonder A; Hobbs M; Hwa Y; Gonsalves W; Warsame R; Muchtar E; Leung N; Kyle RA; Rajkumar SV; Kumar S
    Leukemia; 2022 Mar; 36(3):873-876. PubMed ID: 34635783
    [No Abstract]   [Full Text] [Related]  

  • 12. Outcomes of VD-PACE With Immunomodulatory Agent as a Salvage Therapy for Relapsed/Refractory Multiple Myeloma.
    Abdallah AO; Sigle M; Mohyuddin GR; Coggins E; Remker C; Shune L; Mahmoudjafari Z; McGuirk J; Ganguly S
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e220-e226. PubMed ID: 33093009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front-line regimens using the SEER-Medicare data.
    Goto D; Khairnar R; Yared JA; Yong C; Romanus D; Onukwugha E; Slejko JF
    Cancer Med; 2020 Jan; 9(2):626-639. PubMed ID: 31801177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The real-world outcomes of multiple myeloma patients treated with daratumumab.
    Szabo AG; Klausen TW; Levring MB; Preiss B; Helleberg C; Breinholt MF; Hermansen E; Gjerdrum LMR; Bønløkke ST; Nielsen K; Kjeldsen E; Iversen KF; Teodorescu EM; Dokhi M; Kurt E; Strandholdt C; Andersen MK; Vangsted AJ
    PLoS One; 2021; 16(10):e0258487. PubMed ID: 34644367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma.
    Ntanasis-Stathopoulos I; Terpos E; Dimopoulos MA
    Cancer J; 2019; 25(1):2-10. PubMed ID: 30694854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low frequency of CD3
    Lee SE; Lim JY; Ryu DB; Kim TW; Park SS; Jeon YW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min CK
    Ann Hematol; 2018 Nov; 97(11):2163-2171. PubMed ID: 29938309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
    Gandhi UH; Cornell RF; Lakshman A; Gahvari ZJ; McGehee E; Jagosky MH; Gupta R; Varnado W; Fiala MA; Chhabra S; Malek E; Mansour J; Paul B; Barnstead A; Kodali S; Neppalli A; Liedtke M; Narayana S; Godby KN; Kang Y; Kansagra A; Umyarova E; Scott EC; Hari P; Vij R; Usmani SZ; Callander NS; Kumar SK; Costa LJ
    Leukemia; 2019 Sep; 33(9):2266-2275. PubMed ID: 30858549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.
    Oostvogels R; Jak M; Raymakers R; Mous R; Minnema MC
    Br J Haematol; 2018 Oct; 183(1):60-67. PubMed ID: 30080247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study.
    Jourdes A; Cellerin E; Touzeau C; Harel S; Denis B; Escure G; Faure E; Jamard S; Danion F; Sonntag C; Ader F; Karlin L; Soueges S; Cazelles C; de La Porte des Vaux C; Frenzel L; Lanternier F; Brousse X; Cazaubiel T; Berger P; Collignon A; Blot M; Pieragostini A; Charles M; Chaleteix C; Redor A; Roland V; Cartau T; Macro M; Chalopin T; Vallet N; Perrot A; Martin-Blondel G;
    Clin Microbiol Infect; 2024 Jun; 30(6):764-771. PubMed ID: 38432433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.